A Randomized, Double-blind, Placebo-Controlled, Single Dose,Dose-escalationPhase 1a Study of the Safety, TolerabilityPharmacokinetics and the Potential Immunological Reaction of Recombinant Human Thymosin Beta4 in Chinese Healthy Volunteers
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Recombinant human thymosin beta4 Beijing Northland Biotech (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Beijing Northland Biotech
- 14 Sep 2020 Status changed from recruiting to completed.
- 18 Jul 2017 New trial record